Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;62(4):703-10.
doi: 10.1053/j.ajkd.2013.04.012. Epub 2013 Jun 12.

Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population

Affiliations

Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population

Jonathan J Taliercio et al. Am J Kidney Dis. 2013 Oct.

Abstract

Background: Elevated total serum alkaline phosphatase (ALP) levels have been associated with mortality in the general population and in dialysis patients.

Study design: Retrospective cohort study.

Setting & participants: 28,678 patients with chronic kidney disease (CKD) stages 3 and 4 (estimated glomerular filtration rate, 15-59 mL/min/1.73 m(2)) were identified using the Cleveland Clinic CKD Registry. CKD was defined as 2 estimated glomerular filtration rate values <60 mL/min/1.73 m(2) drawn more than 90 days apart using the CKD-EPI (CKD Epidemiology Collaboration) creatinine equation.

Predictor: ALP levels measured using the calorimetric assay were examined as quartiles (quartile [Q]1, <66 U/L; Q2, 66-81 U/L; Q3, 82-101 U/L; and Q4, ≥102 U/L) and as a continuous measure.

Outcomes & measurements: All-cause mortality and end-stage renal disease (ESRD) were ascertained using the Social Security Death Index and US Renal Data System.

Results: After a median follow-up of 2.2 years, 588 patients progressed to ESRD and 4,755 died. There was a graded increase in risk of mortality with higher ALP quartiles (Q2, Q3, and Q4) compared to the reference quartile (Q1) after adjusting for demographics, comorbid conditions, use of relevant medications, and liver function test results. The highest ALP quartile was associated with an HR for ESRD of 1.38 (95% CI, 1.09-1.76). Each 1-SD (42.7 U/L) higher ALP level was associated with 15% (95% CI, 1.09-1.22) and 16% (95% CI, 1.14-1.18) increased risk of ESRD and mortality, respectively.

Limitations: Single-center observational study; lack of complete data, including parathyroid hormone level, for all study participants, and attrition bias.

Conclusions: Higher serum ALP levels in patients with CKD stages 3-4 were associated independently with all-cause mortality and ESRD.

Keywords: Alkaline phosphatase; chronic kidney disease; end-stage renal disease; mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart showing how patients were selected for this analysis.
Figure 2
Figure 2
Cumulative incidence curves for ESRD and all-cause mortality for those with different levels of alkaline phosphatase
Figure 3
Figure 3
Associations of ALP with mortality based on the stage of CKD

References

    1. Jono S, Shioi A, Ikari Y, Nishizawa Y. Vascular calcification in chronic kidney disease. J Bone Miner Metab. 2006;24(2):176–181. - PubMed
    1. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP. Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010;(117):S10–21. - PMC - PubMed
    1. Abramowitz M, Muntner P, Coco M, et al. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol. 2010;5(6):1064–1071. - PMC - PubMed
    1. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120(18):1784–1792. - PubMed
    1. Shantouf R, Kovesdy CP, Kim Y, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1106–1114. - PMC - PubMed

Publication types

Substances